113 results about "AML - Acute myeloid leukemia" patented technology

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).

The invention relates to an acute myeloid leukemia miRNA and transcription factor model and a construction method and application thereof. The construction method includes: acquiring differential expression miRNA and different expression transcription factors of marrow samples of acute myeloid leukemia patients and a healthy contrast group, constructing a miRNA-transcription factor regulatory network model to obtain core miRNA and core transcription factors, and the like. The constructed miRNA and transcription factor model can be used for construction of diagnosis probes, chips or reagents, equipment and the like to provide intermediate result information or reference information for diagnosis of the acute myeloid leukemia patients. By the acute myeloid leukemia miRNA and transcription factor model, microRNA mediated network regulation contents are enriched, and an action mechanism of a microRNA and transcription factor mediated regulation network in AML (acute myeloid leukemia) is revealed. Research results lay the foundation for development of anti-leukemia medicines or biological products, and high application value is achieved.

In alternative embodiment, provided are methods and compositions for treating, ameliorating or preventing diseases and conditions, such as cancer, including cancers associated with stem cells such as, without limitation, myelodysplastic syndrome (MDS) and a myeloproliferative neoplasm like chronic myeloid leukemia (CML) or acute myeloid leukemia (AML), and ablating or killing cancer stem cells. In alternative embodiment, provided are a new set of biomarkers to detect leukemia stem cell reprogramming and CML progression. In alternative embodiment, provided are therapeutic targets for treating myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML) by targeting edited let-7 transcripts.

The invention belongs to the technical field of medicines and in particular relates to a type of novel steroid saponin compounds and an application thereof. The steroid saponin compounds are prepared by the steps: performing degreasing treatment on solanum nigrum green fruits, performing solvent extraction, eluting by using a D101 macroporous resin column, separating through repeated silica gel column chromatography, reversed-phase MPLC (Middle Pressure Liquid Chromatography), Sephadex LH-20 column chromatography, semi-preparative reversed phase HPLC (High Performance Liquid Chromatography) and other means, thereby obtaining the product. Nine compounds with clear chemical structures are identified by virtue of physico-chemical constants and modern spectroscopy means. Pharmacodynamic experiments prove that the nine novel steroid saponin compounds have excellent in-vitro anti-inflammatory activities and have different degrees of tumor inhibiting effects on three tumor strains of human acute myeloid leukemia cells HL-60, human tissue lymphoma cells U937 and human hepatoma cells HepG2. The novel steroid saponin compounds can be further taken as anti-inflammatory and antitumor drugs to be researched and developed.